PURPOSE: Chronic inflammation is linked to the development of cancer in several organs, including the prostate. Up-regulated cyclooxygenase-2 (COX-2) may play a role in influencing cell proliferation, differentiation, apoptosis, or angiogenesis. This study aimed to derive data from human prostate cancer to investigate whether chronic inflammation and angiogenesis were correlated with the expression of COX-2. EXPERIMENTAL DESIGN: In this study, we did double-immunohistochemical analysis of a set of 43 human prostate cancer for COX-2 expression and the correlation with T-lymphocyte and macrophage densities and CD31-marked microvessel density (MVD) in situ. RESULTS: COX-2 positive staining was detected in 40/43 cancer samples with the very heterogeneous expression. Elevated COX-2 expression was associated with high Gleason score (P = 0.002). Foci of chronic inflammation were found in all 43 samples. COX-2-positive areas were noted with high T-lymphocyte and macrophage densities than COX-2-negative tumor areas (P < 0.0001 and P = 0.001, respectively). MVD were also found higher in COX-2-positive areas than in COX-2-negative tumor areas (P = 0.001). CONCLUSIONS: This study shows a novel relationship between COX-2 expression and the local chronic inflammation within prostate cancer and the increased angiogenesis. It is likely that the proinflammatory cytokines, released by T-lymphocytes and macrophages, up-regulate COX-2 in adjacent tumor cells and stimulate the angiogenesis in stromal tissues. These findings suggest that COX-2 may be an effective therapeutic target in prostate cancer treatment.
PURPOSE:Chronic inflammation is linked to the development of cancer in several organs, including the prostate. Up-regulated cyclooxygenase-2 (COX-2) may play a role in influencing cell proliferation, differentiation, apoptosis, or angiogenesis. This study aimed to derive data from humanprostate cancer to investigate whether chronic inflammation and angiogenesis were correlated with the expression of COX-2. EXPERIMENTAL DESIGN: In this study, we did double-immunohistochemical analysis of a set of 43 humanprostate cancer for COX-2 expression and the correlation with T-lymphocyte and macrophage densities and CD31-marked microvessel density (MVD) in situ. RESULTS:COX-2 positive staining was detected in 40/43 cancer samples with the very heterogeneous expression. Elevated COX-2 expression was associated with high Gleason score (P = 0.002). Foci of chronic inflammation were found in all 43 samples. COX-2-positive areas were noted with high T-lymphocyte and macrophage densities than COX-2-negative tumor areas (P < 0.0001 and P = 0.001, respectively). MVD were also found higher in COX-2-positive areas than in COX-2-negative tumor areas (P = 0.001). CONCLUSIONS: This study shows a novel relationship between COX-2 expression and the local chronic inflammation within prostate cancer and the increased angiogenesis. It is likely that the proinflammatory cytokines, released by T-lymphocytes and macrophages, up-regulate COX-2 in adjacent tumor cells and stimulate the angiogenesis in stromal tissues. These findings suggest that COX-2 may be an effective therapeutic target in prostate cancer treatment.
Authors: Leslie Oleksowicz; Yin Liu; R Bruce Bracken; Krishnanath Gaitonde; Barbara Burke; Paul Succop; Linda Levin; Zhongyun Dong; Shan Lu Journal: Prostate Date: 2011-11-29 Impact factor: 4.104
Authors: Naoko Kobayashi; R James Barnard; Susanne M Henning; David Elashoff; Srinivasa T Reddy; Pinchas Cohen; Pak Leung; Jenny Hong-Gonzalez; Stephen J Freedland; Jonathan Said; Dorina Gui; Navindra P Seeram; Laura M Popoviciu; Dilprit Bagga; David Heber; John A Glaspy; William J Aronson Journal: Clin Cancer Res Date: 2006-08-01 Impact factor: 12.531
Authors: Jay H Fowke; Saundra S Motley; Joseph A Smith; Michael S Cookson; Raoul Concepcion; Sam S Chang; Susan Byerly Journal: J Urol Date: 2009-03-14 Impact factor: 7.450